摘要
目的探讨胱抑素C在131I治疗甲亢中的临床应用价值。方法选择2011年2月至2012年10月在我院131I治疗的43例甲亢患者和40例健康者(对照组)进行甲状腺激素、血清胱抑素C(CysC)水平的比较;并观察甲亢患者131I治疗后3个月、6个月与治疗前的甲状腺激素、血清胱抑素C(CysC)与血清肌酐(Cr)水平变化。结果甲亢患者血清CysC水平增高,随着甲亢患者131I治疗后甲状腺激素水平的恢复,血清CysC水平降低(P<0.05)。结论血清胱抑素C(CysC)可以作为甲亢的辅助检测项目和131I治疗后疗效判定的辅助诊治指标。
Objective To investigate the clinical value of cystatin C in 131I treatment of patients with hyperthyroidism. Methods The thyroid hormone level and serum level of Cys C and Cr in 43 patients with hyperthyroidism before and after 3 and 6 months of 131I treatment and in 40 healthy controls were determined. Results The serum Cys C levels in patients with hypothyroidism were higher than that of healthy controls. The thyroid hormone level in patients with hypothyroidism were back to normal and serum Cys C levels were decreased after 131I treatment （ P 〈 0.05 ）. Conclusion Cystatin C can be the auxiliary diagnostic examination item of hyperthyroidism and could be acted as an auxiliary diagnosis index of efficacy evaluation after 1311 treatment.
出处
《标记免疫分析与临床》
CAS
2014年第1期31-32,共2页
Labeled Immunoassays and Clinical Medicine
